Kymera Therapeutics

KYMRNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$10.149 B

$122.06 +3.73%

Close of 22 Sept 2026

Revenue

$39.2M

#2808 by revenue

Earnings

$311.4M

#820 by earnings

Shares outstanding

83,150,618

Latest filing cover page

P/E ratio

32.6

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#12Twist BioscienceTWST$10.9B
#13Krystal BiotechKRYS$10.4B
#14Kymera TherapeuticsKYMR$10.1B
#15ImmunityBioIBRX$9.85B
#16RepligenRGEN$9.14B

What if Kymera Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$363,604.87

Per share 2,979× higher

Bitcoin $1.74T

$20,945.79

Per share 172× higher

Nvidia $5.52T

$66,334.65

Per share 543× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Kymera Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.